TCV Trust & Wealth Management Inc. Increases Position in Becton, Dickinson and Company (NYSE:BDX)

TCV Trust & Wealth Management Inc. increased its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 6.9% during the third quarter, Holdings Channel.com reports. The institutional investor owned 2,313 shares of the medical instruments supplier’s stock after buying an additional 150 shares during the quarter. TCV Trust & Wealth Management Inc.’s holdings in Becton, Dickinson and Company were worth $558,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently made changes to their positions in BDX. Nordea Investment Management AB grew its holdings in shares of Becton, Dickinson and Company by 277.3% during the first quarter. Nordea Investment Management AB now owns 1,936,654 shares of the medical instruments supplier’s stock valued at $478,295,000 after buying an additional 1,423,353 shares during the last quarter. PineStone Asset Management Inc. grew its holdings in shares of Becton, Dickinson and Company by 141.6% during the second quarter. PineStone Asset Management Inc. now owns 1,345,873 shares of the medical instruments supplier’s stock valued at $314,544,000 after buying an additional 788,735 shares during the last quarter. M&G Plc purchased a new stake in shares of Becton, Dickinson and Company during the first quarter valued at $173,692,000. First Eagle Investment Management LLC grew its holdings in shares of Becton, Dickinson and Company by 32.5% during the second quarter. First Eagle Investment Management LLC now owns 2,803,255 shares of the medical instruments supplier’s stock valued at $655,149,000 after buying an additional 688,296 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its position in Becton, Dickinson and Company by 8.5% during the second quarter. Bank of New York Mellon Corp now owns 4,412,163 shares of the medical instruments supplier’s stock valued at $1,031,167,000 after purchasing an additional 346,720 shares during the period. 86.97% of the stock is owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Stock Down 0.2 %

BDX opened at $238.13 on Friday. Becton, Dickinson and Company has a twelve month low of $218.75 and a twelve month high of $259.92. The company has a quick ratio of 1.36, a current ratio of 1.85 and a debt-to-equity ratio of 0.70. The company has a 50-day moving average price of $237.46 and a 200 day moving average price of $235.08. The company has a market cap of $68.82 billion, a PE ratio of 52.45, a price-to-earnings-growth ratio of 1.79 and a beta of 0.42.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share for the quarter, topping the consensus estimate of $3.31 by $0.19. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The firm had revenue of $4.99 billion during the quarter, compared to the consensus estimate of $5.08 billion. During the same quarter in the prior year, the firm earned $2.96 EPS. The company’s revenue for the quarter was up 2.3% on a year-over-year basis. Sell-side analysts expect that Becton, Dickinson and Company will post 13.11 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. Citigroup upgraded shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and boosted their target price for the company from $255.00 to $275.00 in a research report on Tuesday, October 1st. Raymond James decreased their target price on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a research report on Friday, August 2nd. Stifel Nicolaus boosted their target price on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a research report on Friday, July 26th. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Finally, Evercore ISI upped their price objective on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $282.63.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.